Biomedical device maker SetPoint Medical is moving into the Mann Biomedical Park in Santa Clarita, joining companies like Boston Scientific, the Alfred Mann Foundation, MannKind and Bioness.
SetPoint is working on treating patients with debilitating inflammatory diseases, such as Crohn's Disease and rheumatoid arthritis, through the use of bioelectronic therapy using a proprietary, implantable device that helps regulate the central nervous system, which in turn regulates the body’s immune system.
“We are in the process of moving into the building,” said SetPoint Medical CEO Anthony Arnold. “It’s a disruption to move, but we need more space; we’ve grown, which is a sign that we have a lot more activity going on.”
Moving into 14,000 square feet of space, SetPoint has 25 employees. It signed a deal with park owner, Intertex, with the help of broker Tim Crissman from Crissman Commercial Services, Arnold said.
“The park appeared to be the best space we could get for what we needed to do,” he said.
Last August, SetPoint raised $15 million in Series C equity financing, bringing the total the firm had raised to $43 million. Investors in the company include Morgenthaler Ventures, Foundation Medical Partners, Topspin Partners, Boston Scientific, Covidien and Action Potential Venture Capital.
“We signed a deal and we’re getting permits and construction done,” Arnold said. “Hopefully, we will be able to move into the space around the August-September timeframe.”

